Korro Bio's Drug Trial Fails, Company Restructures
Update: 2025-11-12
Description
Korro Bios stock plummeted by 80% after disappointing clinical trial results for their Alpha-one Antitrypsin Deficiency drug, KRRO-one-ten. The drug only increased protein levels by 2 micromolars, far below the protective 11 micromolars. The company is now shifting focus to a new drug candidate and has announced a new drug for hyperammonemia. Korro Bio is undergoing a major restructuring, reducing its workforce by one-third, to extend its financial resources.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
